01699nam0 22003133i 450 SUN011497520180926101415.635978-92-87183-27-90.0020180216d2017 |0engc50 baengFR|||| |||||*European PharmacopoeiaSupplement 9.3published in accordance with the Convention on the elaboration of a European Pharmacopoeia (European treaty series No50)9. edStrasbourgCouncil of Europe2017XXXVII-XL, 4683-5096 p.30 cm001SUN01149722001 *European pharmacopoeiapublished in accordance with the Convention on the elaboration of a European Pharmacopoeia (European treaty series No50)9.3205 9. ed210 StrasbourgCouncil of Europe2016215 volumi30 cm.StrasburgoSUNL001124615.11Farmacopee22Council of EuropeSUNV033189EDQMSUNV088981Council of EuropeSUNV001822650European Directorate for the Quality of Medicines & HealtCareEDQMSUNV088982ITSOL20190408RICASUN0114975UFFICIO DI BIBLIOTECA DEL DIPARTIMENTO DI SCIENZE E TECNOLOGIE AMBIENTALI BIOLOGICHE E FARMACEUTICHE17PREST Ua131 17BIB1911 20180619 BuonoUFFICIO DI BIBLIOTECA DEL DIPARTIMENTO DI SCIENZE E TECNOLOGIE AMBIENTALI BIOLOGICHE E FARMACEUTICHE17CONS Ua123 17BIB1910 20180619 BuonoEuropean pharmacopoeia724240UNICAMPANIA04802nam 2200649Ia 450 991101999960332120200520144314.01-283-83537-13-527-63389-83-527-63388-X(CKB)3400000000000401(EBL)661793(OCoLC)768731436(SSID)ssj0000507243(PQKBManifestationID)11303294(PQKBTitleCode)TC0000507243(PQKBWorkID)10545717(PQKB)11256023(MiAaPQ)EBC661793(EXLCZ)99340000000000040120110808d2011 uy 0engur|n|---|||||txtccrApicomplexan parasites molecular approaches toward targeted drug development /edited by Katja Becker4th ed.Weinheim Wiley-Blackwellc20111 online resource (552 p.)Drug discovery in infectious diseases ;v. 2Description based upon print version of record.3-527-32731-2 Includes bibliographical references and index.Apicomplexan Parasites: Molecular Approaches toward Targeted Drug Development; Foreword; Contents; Preface; List of Contributors; Part One: Screening, Bioinformatics, Chemoinformatics, and Drug Design; 1 Drug Discovery Approaches Toward Anti-Parasitic Agents; 2 New Bioinformatic Strategies Against Apicomplexan Parasites; 3 Sorting Potential Therapeutic Targets in Apicomplexa; 4 Alternatives to Drug Development in the Apicomplexa; Part Two: Metabolic Pathways and Processes Addressed by Current Drug Discovery Approaches; 5 Energy Metabolism as an Antimalarial Drug Target6 Polyamines in Apicomplexan Parasites7 The Reducing Milieu of Parasitized Cells as a Target of Antimalarial Agents: Methylene Blue as an Ethical Drug; 8 Lipids as Drug Targets for Malaria Therapy; 9 Targeting Apicoplast Pathways in Plasmodium; 10 Lipoic Acid Acquisition and Glutathione Biosynthesis in Apicomplexan Parasites; 11 Antimalarial Drugs and Molecules Inhibiting Hemozoin Formation; 12 Exploiting the Vitamin Metabolism of Apicomplexa as Drug Targets; 13 Vitamin Biosynthetic Pathways, the PLP Synthase Complex, and the Potential for Targeting Protein-Protein Interaction14 Targeting Prokaryotic Enzymes in the Eukaryotic Pathogen CryptosporidiumPart Three: Drug Targets in Apicomplexan Parasites; 15 Novel Apicomplexan Phosphatases and Immunophilins as Domain-Specific Drug Targets; 16 Dehydrogenases and Enzymes of the Mitochondrial Electron Transport Chain as Anti-Apicomplexan Drug Targets; 17 Calcium-Dependent Protein Kinases as Drug Targets in Apicomplexan Parasites; 18 Protein Acylation: New Potential Targets for Intervention Against the Apicomplexa; 19 Drugs and Drug Targets in Neospora caninum and Related Apicomplexans; Part Four: Compounds20 Subversive Substrates of Glutathione Reductases from Plasmodium falciparum-Infected Red Blood Cells as Antimalarial Agents21 Ferroquine: A Concealed Weapon; 22 Current Aspects of Endoperoxides in Antiparasitic Chemotherapy; 23 Plasmodium Hsp90 as an Antimalarial Target; 24 Drug Discovery Against Babesia and Toxoplasma; 25 Search for Drugs and Drug Targets against Babesia bovis, Babesia bigemina, Babesia caballi, and Babesia (Theileria) equi; 26 Orlistat: A Repositioning Opportunity as a Growth Inhibitor of Apicomplexan Parasites?; 27 Recent Drug Discovery Against Cryptosporidium; IndexThis handbook is the first dealing with the discovery of drugs directed against apicomplexan parasites. Amongst others, this group of endoparasites includes the causative agents of Malaria, Toxoplasmosis, and Babesiosis, the latter occurring mainly in animals. Written by renowned scientific experts from academia and industry, the book focuses on currentdrug development approaches for all apicomplexan diseases making it appealing to a large audience, ranging from research labs in academia to the human and veterinarian pharmaceutical industry. This work is the second volume of the new book seriDrug discovery in infectious diseases ;v. 2.Antiprotozoal agentsProtozoan diseasesChemotherapyApicomplexaDrug developmentAntiprotozoal agents.Protozoan diseasesChemotherapy.Apicomplexa.Drug development.616.9/6Becker Katja1965-1838885MiAaPQMiAaPQMiAaPQBOOK9911019999603321Apicomplexan parasites4417972UNINA